Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours:: a prospective, randomised, multicentre trial

被引:740
|
作者
van der Zee, J
González, DG
van Rhoon, GC
van Dijk, JDP
van Putten, WLJ
Hart, AAM
机构
[1] Univ Amsterdam, Acad Med Ctr, Subdiv Hyperthermia, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Radiat Oncol, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Stat, NL-1105 AZ Amsterdam, Netherlands
来源
LANCET | 2000年 / 355卷 / 9210期
关键词
D O I
10.1016/S0140-6736(00)02059-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Local-control rates after radiotherapy for locally advanced tumours of the bladder, cervix, and rectum are disappointing. We investigated the effect of adding hyperthermia to standard radiotherapy. Methods The study was a prospective, randomised, multicentre trial. 358 patients were enrolled from 1990 to 1996, in cancer centres in the Netherlands, who had bladder cancer stages T2, T3, or T4, N0, M0, cervical cancer stages IIB, IIIB, or IV, or rectal cancer stage M0-1 were assessed. Patients were randomly assigned radiotherapy (median total dose 65 Gy) alone (n=176) or radiotherapy plus hyperthermia (n=182). Our primary endpoints were complete response and duration of local control. We did the analysis by intention to treat. Findings Complete-response rates were 39% after radiotherapy and 55% after radiotherapy plus hyperthermia (p<0.001). The duration of local control was significantly longer with radiotherapy plus hyperthermia than with radiotherapy alone (p=0.04). Treatment effect did not differ significantly by tumour site, but the addition of hyperthermia seemed to be most important for cervical cancer, for which the complete-response rate with radiotherapy plus hyperthermia was 83% compared with 57% after radiotherapy alone (p=0.003). 3-year overall survival was 27% in the radiotherapy group and 51% in the radiotherapy plus hyperthermia group. For bladder cancer, an initial difference in local control disappeared during follow-up. Interpretation Hyperthermia in addition to standard radiotherapy may be especially useful in locally advanced cervical tumours. Studies of larger numbers of patients are needed for other pelvic tumour sites before practical recommendations can be made.
引用
收藏
页码:1119 / 1125
页数:7
相关论文
共 50 条
  • [31] Comparison of concomitant boost radiotherapy against concurrent chemoradiation in locally advanced oropharyngeal cancers: A phase III randomised trial
    Rishi, Anupam
    Ghoshal, Sushmita
    Verma, Roshan
    Oinam, Arun S.
    Patil, Vijai M.
    Mohinder, Rakesh
    Sharma, Suresh C.
    RADIOTHERAPY AND ONCOLOGY, 2013, 107 (03) : 317 - 324
  • [32] LUNG-CANCER - CLINICAL TRIAL OF RADIOTHERAPY ALONE VS RADIOTHERAPY PLUS CYCLOPHOSPHAMIDE
    BERGSAGEL, DE
    WHITE, DM
    FETTERLY, JC
    PRINGLE, JF
    MCDERMOT, RS
    KLAASSEN, DJ
    JENKIN, RDT
    CANCER, 1972, 30 (03) : 621 - +
  • [33] PROSPECTIVE TRIAL OF SYNCHRONOUS CAPECITABINE, RADIOTHERAPY AND BEVACIZUMAB FOR LOCALLY ADVANCED RECTAL CANCER (CRAB)
    Velenik, Vaneja
    Ocvirk, Janja
    Music, Maja
    Matej, Bracko
    Anderluh, Franc
    Oblak, Irena
    Edhemovic, Ibrahim
    Brecelj, Erik
    Kropivnik, Mateja
    Omejc, Mirko
    ANNALS OF ONCOLOGY, 2012, 23 : 113 - 113
  • [34] Hyperthermia combined with radiotherapy and chemotherapy in the locally advanced, recurrent or metastatic disease
    Maluta, S.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 (05) : 477 - 477
  • [35] A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer
    Cakir, S
    Egehan, I
    LUNG CANCER, 2004, 43 (03) : 309 - 316
  • [36] A randomised controlled trial of elemental diet during pelvic radiotherapy
    McGough, C.
    Baidwint, C.
    Hackett, C.
    Wedlake, L.
    Norman, A.
    Frost, G.
    Blake, P.
    Tai, D.
    Khoo, V.
    Harrington, K.
    Andreyev, H. J. N.
    CLINICAL ONCOLOGY, 2007, 19 (03) : S11 - S11
  • [38] A Swiss multicentre phase II study of capecitabine plus oxaliplatin (CAPOX) in combination with preoperative pelvic radiotherapy in patients (pts) with locally advanced rectal cancer
    Koeberle, D.
    Burkhard, R.
    Von Moos, R.
    Winterhalder, R.
    Hess, V.
    Heitzmann, F.
    Ruhstaller, T.
    Terraciano, L.
    Bieri, G.
    Toepfer, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 244 - 244
  • [39] Local recurrence rate in a randomised multicentre trial of preoperative radiotherapy compared with operation alone in resectable rectal carcinoma
    Pahlman, L
    Glimelius, B
    Cedermark, B
    Lundell, G
    Rieger, A
    Rutquist, LE
    Theve, T
    Wilking, N
    Bengtsson, NO
    Blomgren, H
    Rubio, C
    Ost, A
    Brismar, B
    Wikstrom, B
    Ewerth, S
    Dahlgren, S
    Forsgren, L
    Friberg, S
    Johansson, C
    Magnusson, I
    Sundelin, P
    Svensson, C
    Tornberg, B
    Fenyo, G
    Ljungdahl, I
    Svensson, SO
    Molin, K
    Goldman, S
    Lasarett, V
    Bark, S
    Robertsson, B
    Dalen, J
    Raf, L
    Ohman, U
    Nilsson, SE
    Westman, M
    Liljeholm, H
    Bendzen, O
    Ljunquist, U
    Nihlberg, A
    Heuman, R
    Lorentz, T
    BisgaardPedersen, A
    Bergstrom, S
    Krog, M
    Tuvesson, T
    Edman, P
    Lindstrom, C
    Sandhammar, B
    Tyden, G
    EUROPEAN JOURNAL OF SURGERY, 1996, 162 (05) : 397 - 402
  • [40] Erlotinib plus radiotherapy in patients with locally advanced rectal cancer
    Smorenburg, CH
    Van Triest, B
    Van der Sijp, JRM
    Van Groeningen, CJ
    Giaccone, G
    ANNALS OF ONCOLOGY, 2005, 16 : 40 - 40